Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (G Altimmune ( NASDAQ:ALT ) Third Quarter 2024 Results Key Financial Results Net loss ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

Binance Coin (BNB) surges 15% following a $2 billion investment from MGX, boosting investor confidence and pushing BNB closer ...

[Fantasy Baseball Draft Rankings: C | 1B | 2B | 3B | SS | OF | SP | RP] At 32 years old, maybe his best days are behind him — or, maybe 2024 was an outlier, and Betts will once again be an ADP gift.

Consumption of non-dairy alternatives witnessed a dip at the start of the year, while conventional products like whole milk ...

Vir Biotechnology, Inc. today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and ...

After hours: March 14 at 6:00:00 PM EDT Loading Chart for KEYS ...

NORTH KEY LARGO — A voracious invasive predator that state and federal wildlife officials feared would one day find a home in the Florida Keys has established residency.

and the film's Los Angeles premiere at TCL Chinese Theatre Getty Images Chinese blockbuster Ne Zha 2 recently became the first non-Hollywood movie to cross $2B worldwide, and in so doing joins an ...